MaxCyte, Inc. reported a challenging fiscal year 2025, with total revenue declining 15% to $33 million, driven by significant headwinds from discontinued Strategic Platform Licenses (SPL) and a major customer restructuring. CEO Maher Masoud highlighted a $4 million core revenue impact due to these SPL program discontinuations and a 15% drop in purchases from their largest customer. Looking ahead, the company anticipates total revenue for 2026 to fall between $30 million and $32 million, with core revenue projected at $25 million to $27 million.
Despite the revenue decline, MaxCyte is focusing on innovation, launching the Xpert DTX, a modular electroporation platform aimed at enhancing early-stage research. This product is expected to contribute positively to revenue in the latter half of 2026, alongside ongoing clinical programs that could yield over $110 million in milestone payments. The company’s cash position remains strong, with $155.6 million at year-end and no debt, allowing for continued investment in product development.
For market professionals, the key takeaway is that while MaxCyte faces near-term revenue challenges, its strategic focus on innovation and a robust pipeline of SPL agreements may position it for recovery and growth in the coming years.
Source: fool.com